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Background: Methylated resveratrol analogs show similar biological activities that are comparable with those of
the resveratrol. However, the methylated resveratrol analogs exhibit better bioavailability as they are more easily
transported into the cell and more resistant to degradation. Although these compounds are widely used in human
health care and in industrial materials, at present they are mainly obtained by extraction from raw plant sources.
Accordingly their production can suffer from a variety of economic problems, including low levels of productivity
and/or heterogeneous quality. On this backdrop, large-scale production of plant metabolites via microbial approaches
is a promising alternative to chemical synthesis and extraction from plant sources.
Results: An Escherichia coli system containing an artificial biosynthetic pathway that produces methylated
resveratrol analogues, such as pinostilbene (3,4’-dihydroxy-5-methoxystilbene), 3,5-dihydroxy-4’-methoxystilbene,
3,4’-dimethoxy-5-hydroxystilbene, and 3,5,4’-trimethoxystilbene, from simple carbon sources is developed. These
artificial biosynthetic pathways contain a series of codon-optimized O-methyltransferase genes from sorghum in
addition to the resveratrol biosynthetic genes. The E. coli cells that harbor pET-opTLO1S or pET-opTLO3S produce
the one-methyl resveratrol analogues of 3,5-dihydroxy-4’-methoxystilbene and pinostilbene, respectively. Furthermore,
the E. coli cells that harbor pET-opTLO13S produce 3,5-dihydroxy-4’-methoxystilbene, bis-methyl resveratrol
(3,4’-dimethoxy-5-hydroxystilbene), and tri-methyl resveratrol (3,5,4’-trimethoxystilbene).
Conclusions: Our strategy demonstrates the first harness microorganisms for de novo synthesis of methylated
resveratrol analogs used a single vector system joined with resveratrol biosynthetic genes and sorghum two resveratrol
O-methyltransferase genes. Thus, this is also the first report on the production of the methylated resveratrol compounds
bis-methyl and tri-methyl resveratrol (3,4’-dimethoxy-5-hydroxystilbene and 3,5,4’-trimethoxystilbene) in the E. coli culture.
Thus, the production of the methylated resveratrol compounds was performed on the simple E. coli medium without
precursor feeding in the culture.Background
Resveratrol (3,5,4’-trihydroxystilbene), which is found in
red wine and grapes as well as in other plants, has been
the subject of intensive studies that focus on its possible
role in preventing cardiovascular heart diseases and
cancer [1]. Resveratrol and its analogs have important* Correspondence: hongsoo@kribb.re.kr
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unless otherwise stated.functions as antimicrobial and antioxidant compounds
in plant defense responses to environmental stresses,
such as UV irradiation and fungal infection. However, they
also exhibit diverse beneficial properties in humans, in-
cluding anti-inflammatory effects, anti-tumor activities,
and anti-aging effects [2]. In particular, over the past dec-
ade, resveratrol has been used as a dietary supplement that
has been demonstrated to possess a broad spectrum of
pharmacological properties [3,4]. However, Walle et al.
reported the high absorption but rapid metabolism of
resveratrol when it was administered orally to humans [5].
Several reports have demonstrated that the methylation ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ability and bioactivity [6,7]. For example, pterostilbene
is a 3,5 bis-methylated resveratrol that is present in
blueberries and it has been investigated extensively [8].
The substitution of the hydroxy with the methoxy
groups increases the lipophilicity of pterostilbene over
the resveratrol, which results in high bioavailability.
These differences in the pharmacokinetics might ex-
plain the higher biological activity of pterostilbene over
its parental compound resveratrol [9]. Furthermore, 3,5,
4’-trimethoxystilbene has emerged as the most potent
proapoptotic analog of resveratrol [10]. In addition,
3,5,4’-trimethoxystilbene and pinostilbene (3,4’-dihy-
droxy-5-methoxystilbene) were reported to be up to
100-fold more cytotoxic than resveratrol in cancer cell
lines [11]. Consequently, methylated resveratrol ana-
logs, which can possess greater oral bioavailability due
to their decreased metabolism and increased absorption,
have garnered increasing attention as alternative chemo-
preventive agents. Therefore, methylated resveratrols have
become an attractive target for bioengineering, but fewFigure 1 Engineered biosynthetic pathways for the methylated resve
ammonia-lyase) from S. espanaensis, CCL (4-coumarate:CoA ligase) from S. c
sbOMT3 (resveratrol O-methyltransferases) from S. bicolor.attempts to characterize the methylation enzyme of
resveratrol have been reported thus far [12-17].
Methylated resveratrol is biosynthesized from the gen-
eral phenylpropanoid pathway beginning with phenyl-
alanine or tyrosine, or both. The methylated resveratrol
biosynthesis pathway designed for use in this study is
depicted in Figure 1. In this pathway, tyrosine is con-
verted into 4-coumaric acid using tyrosine ammonia
lyase (TAL). The 4-coumaric acid is then activated to
4-coumaroyl-CoA using the 4-coumarate-CoA ligase
(4CL). This 4-coumaroyl-CoA is condensed with three
molecules of malonyl-CoA via stilbene synthase (STS),
which is the key enzyme in resveratrol synthesis. Resvera-
trol is converted into its methylated derivatives through
the resveratrol O-methyltransferase. Meanwhile, several
attempts to produce resveratrol using recombinant
microorganisms, such as Escherichia coli [18-23] and
Saccharomyces cerevisiae [24,25], have been reported.
However, little has been reported about the characterization
of the resveratrol O-methyltransferase function in plants
[13-15,17]. Recently, the sbOMT1 and sbOMT3 genes fromratrol analogs starting from tyrosine in E. coli. TAL (tyrosine
oelicolor, STS (stilbene synthases) from A. hypogaea, and sbOMT1 &
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characterized as different resveratrol O-methyltransferases
(ROMTs), respectively [12,13,16]. Furthermore, Katsuyama
et al. reported the production of the methylated resvera-
trols pinostilbene and pterostilbene in recombinant E. coli
using the pinosylvin methyltransferase (OsPMT) gene
from Oryza sativa and the tyrosine feeding method in a
culture medium [15].
In this study, we describe the production of the meth-
ylated resveratrol analogs of pinostilbene, 3,5-dihy-
droxy-4’-methoxystilbene, 3,4’-dimethoxy-5-hydroxystil
bene, and 3,5,4’-trimethoxystilbene using the recom
binant E. coli that harbors an artificial biosynthetic
pathway. These artificial biosynthetic pathways contain
a series of codon-optimized sbOMT1 or sbOMT3 O-
methyltransferase genes, and both O-methyltransferase
genes from sorghum in addition to the resveratrol
biosynthetic gene cluster. The recombinant E. coli pro-
duces methylated resveratrol analogs beginning with
the simple sugar fermentation, but not in the biocon-
version of the intermediates.
Results and discussion
Characterization of the resveratrol O-methyltransferase
via a bioconversion experiment in recombinant E. coli
Previous reports have noted that the two resveratrol
O-methyltransferase genes (sbOMT1 and sbOMT3) from
Sorghum bicolor are capable of using resveratrol as a
substrate that yields methylated analogs of resveratrol
[12,13]. It was claimed that the sbOMT3 O-methyltrans-
ferase catalyzes the A-ring specific 3,5-bis-O-methyla-
tion of resveratrol, which in turn yields pterostilbene
(3,5-dimethoxy-4’-hydroxystilbene) in the co-expressionFigure 2 Expression vectors of O-methyltransferase and organization
methylated analogs of resveratrol in E. coli. All constructs contained the
of each gene. B, BamHI; Bg, BglII; H, HindIII; P, PacI; S, SpeI; N, NdeI; X, XhoI.system of sbOMT3 with a stilbene synthase from peanuts
(AhSTS3) [13]. In addition, sbOMT1, which had previ-
ously been identified as a potential eugenol O-methyl-
transferase, predominantly catalyzes the resveratrol B-ring
(4’-O-methylation), which yields 3,5-dihydroxy-4’-methox-
ystilbene [12,13].
In this study, the functions of the codon-optimized
resveratrol O-methyltransferase genes (sbOMT1 and
sbOMT3) were re-evaluated using a bioconversion
experiment with resveratrol in recombinant E. coli.
The codon-optimized synthetic sbOMT1 and sbOMT3
genes were cloned in the expression vector pET-22b(+)
on the NdeI/HindIII sites (pET22-sbCOM1 and pET22-
sbCOM3, respectively; Figure 2). Each construct was
transformed in the E. coli C41 (DE3) cells, and the recom-
binant E. coli was selected based on the expression ana-
lysis using SDS-PAGE (Additional file 1: Figure S1). In
order to investigate whether the recombinant O-methyl-
transferases can catalyze the production of methylated
resveratrol derivatives, resveratrol was added to the
cultured recombinant E. coli harboring pET22-sbCOM1
and pET22-sbCOM3. The culture broth and bacterial
cells were collected after 36 hours and were then sub-
jected to HPLC and LC/MS analyses (Figure 3). Under
the bioconversion conditions employed in this study
most of the feeding resveratrol disappeared and each
methylated form was detected as a main peak in the
HPLC (Figure 3A). However, when the bioconversion rate
was calculated based on a quantitative comparison with
feeding substrates and the products, the recombinant
E. coli harboring pET22-sbCOM1 and pET22-sbCOM3
showed roughly 42% and 12% conversion ratios, re-
spectively (data not shown). These bioconversion ratiosof the artificial gene clusters used for the production of each
T7 promoter, RBS in front of each gene, and T7 terminator at the rear
Figure 3 HPLC profile (A) and selected mass ion chromatogram (B) of bioconversion experiments. A; HPLC profile of the (a) standard
resveratrol, (b) pinostilbene, and (c) pterostilbene; (d) resveratrol supplemented E. coli harboring pET22-sbCOM1; (e) resveratrol supplemented E. coli
harboring pET22-sbCOM3. The absorbance was monitored at 300 nm. Peak 1, resveratrol; peak 2, pinostilbene; peak 3, 3,5-dihydroxy-4’-methoxystilbene;
peak 4, pterostilbene. B; Selected mass ion chromatogram of (a) 3,5-dihydroxy-4’-methoxystilbene (m/z 243.05 [M+ H]+) produced by E. coli harboring
pET22-sbCOM1; (b) pinostilbene (m/z 243.08 [M+ H]+) and (c) pterostilbene (m/z 257.13 [M +H]+) produced by E. coli harboring pET22-sbCOM3. The
minor peak of 15.9 min in the HPLC profile (d) was not seen in the mass ion peaks of pterostilbene.
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et al. [16]. It is presumed that a significant amount
of additive resveratrol was decomposed in the E. coli
culture medium.
The recombinant E. coli cells that harbored the
pET22-sbCOM1 plasmid produced a 12.2 min reten-
tion time peak, which is a slightly later retention time
than the pinostilbene (3,4’-dihydroxy-5-methoxystilbene)
as seen in Figure 3A(d). The major peak in Figure 3A(d)
exhibited parent mass ion peaks at m/z 243.05 [M+H]+,
which corresponded to one methylation of resveratrol
(an addition of 14 Da; Figure 3B(a)). It was expected
that this methylated compound could have a methoxy
group located in the 4’ position in the B-ring (Figure 1).
In the pET22-sbCOM3 clone, a major peak was present
at the same retention time (11.6 min) as that in the
HPLC analysis and at the same mass ion peaks at m/z
243.08 [M + H]+ with authentic pinostilbene, which is
one methylation of resveratrol (Figure 3B(b)). However,
this recombinant produced a very low level minor peak
of 15.9 min in the HPLC, which was the same retention
time as the pterostilbene (3,5-dimethoxy-4’-hydroxystil-
bene; Figure 3A(e)). This minor peak was also accepted
based on the mass spectra as m/z 257.13 [M + H]+,
which corresponded to two methylations of resveratrol
(an addition of 28 Da; Figure 3B(c)). However, the peakintensity was not sufficient to allow a detailed structural
characterization. These results exhibit a controversial
conclusion that contrasts with the results reported pre-
viously by Rimando et al., who demonstrated that the
sbOMT3 produced pterostilbene as a major product
[13]. However, our results agreed with Jeong et al.’s
reported results with the in vitro and bioconversion
activity of the sbOMT3 [16].
Construction of artificial biosynthetic pathways for the
production of methylated resveratrol analogs in E. coli
We have previously produced resveratrol in E. coli har-
boring an artificial biosynthetic gene cluster in which
the TAL from Saccharothrix espanaensis, CCL from
Streptomyces coelicolor, and STS from the peanut plant
Arachis hypogaea were contained [18]. In order to pro-
duce the methylated resveratrol analogs in E. coli using
a simple sugar medium, a series of plasmids containing
the artificial biosynthetic pathway were constructed
(Figure 2). The artificial resveratrol and methylated
resveratrol biosynthetic plasmids were constructed
using the previously described cloning methods [18],
and each plasmid contained genes with their own T7
promoter, ribosome-binding site (RBS), and terminator
sequence as in the parental vectors. In this study, a
new resveratrol-producing construct of pET-opTLS,
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and cloned ccl gene from S. coelicolor, was constructed
using previously reported cloning method of the par-
ental vector pET-TLkS [18]. The E. coli cells with the
pET-opTLS clone exhibited a higher production yield
of resveratrol (5.2 mg/L) in the culture system with
a modified M9 medium compared with the original
pET-TLkS clone (1.4 mg/L) [18]. The cause of this
improvement remains unknown, but it is possible that
these protein expression ratios may have better opti-
mized the resveratrol production than the original
combination.
In order to construct an expression vector that con-
tains the additional O-methyltransferase gene(s) that
are under the control of the T7 promoter, the DNA
fragment containing the promoter, O-methyltransferase
coding region, and terminator using pET22-sbCOM1
and pET22-sbCOM3 plasmids as templates were ampli-
fied. Then, the amplified fragments were inserted into
pET-opTLS, which resulted in pET-opTLO1S and pET-
opTLO3S, respectively. Similarly, in order to construct the
plasmid containing the two O-methyltransferases biosyn-
thetic pathways, the O-methyltransferase fragment con-
taining the sbOMT3 coding region was inserted into
the pET-opTLO1S, which resulted in pET-opTLO13S.
This is useful assembly method for the reconstruction
of multi-enzyme biosynthetic pathways such as stil-
benes and flavones biosynthesis.Figure 4 HPLC profile of methylated resveratrol analogs in recombina
pinostilbene, and (c) pterostilbene; (d) culture extract of E. coli harboring p
(f) culture extract of E. coli harboring pET-opTLO13S in M9 medium. The abso
peak 2, pinostilbene; peak 3, 3,5-dihydroxy-4’-methoxystilbene; peak 4, pterostThe recombination cells that harbor the artificial bio-
synthetic gene cluster were cultured in a modified M9
medium. A comparison of the fermentation products of
the E. coli cells that harbored pET-opTLS, pET-opTLO1S,
pET-opTLO3S, and pET-opTLO13S revealed that new
peaks were detected in the engineered strain (Figure 4).
The retention times for peaks 1 and 2, which were pro-
duced in the recombinant pET-opTLO3S, were identi-
cal to those of the original resveratrol and pinostilbene,
respectively (Figure 4(e)). These peaks were further
analyzed using LC/MS/MS in the positive ion mode.
Using the LC/MS analysis, peak 1 (resveratrol) and peak 2
(pinostilbene) were identified as m/z 229.02 [M+H]+ and
m/z 243.08 [M+H]+, respectively, when comparing the
obtained fragmentation pattern with that of the original
standards. Furthermore, peak 3, which was produced in
the recombinant pET-opTLO1S and pET-opTLO13S,
was identified as m/z 243.05 [M + H]+ using the LC/MS.
However, the MS/MS analysis of peak 3 exhibited differ-
ent fragments in the ion pattern with the pinostilbene,
and the peaks of m/z 134.88 [M + H]+ that represent
the two hydroxyl group located in the A-ring was also
identified (Figure 5(a)). The fragment ion at m/z 134.88
[M + H]+, which contained the phenolic A-ring of a
compound with a triple bond, has already been reported
as a distinctive mass fragment of resveratrol [26]. The
A-ring cleavage of the resveratrol produced a mass peak of
a triple bond (A-ring) at m/z 134.86 [M+H]+ due to thent E. coli. HPLC profile of (a) the standard resveratrol, (b)
ET-opTLO1S; (e) culture extract of E. coli harboring pET-opTLO3S;
rbance was monitored at 300 nm. p, 4-coumaric acid; peak 1, resveratrol;
ilbene; peak 5, 3,4’-dimethoxy-5-hydroxystilbene.
Figure 5 Mass fragmentation analysis of methylated resveratrol analogs in recombinant E. coli. Structures and MSn spectra of the
predicted analogs produced using the artificial biosynthetic pathways. (a) 3,5-dihydroxy-4’-methoxystilbene; (b) 3,4’-dimethoxy-5-hydroxystilbene;
and (c) standard resveratrol.
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However, due to the presence of a methoxy group in
the A-ring in pinostilbene, the triple bond mass peak
appeared at m/z 148.89 [M + H]+. In addition, peak 5
exhibited a very similar retention time and the same mass
peak (m/z 257.13 [M+H]+) as pterostilbene (Additional
file 1: Figure S2); however, the major daughter ion peaks
of m/z 148.89 [M+H]+ represented one methoxy group
located in the A-ring (Figure 5(b)). Interestingly, the mass
fragmentation pattern of pterostilbene, which was found
in a detectable amount in the bioconversion experiment
with the recombinant pET22-sbCOM3 as mentioned earl-
ier, was not detected in the recombinant pET-opTLO3S
and pET-opTLO13S. These results support that peak 5
was not pterostilbene (3,5-dimethoxy-4’-hydroxystilbene),
but rather that it was 3,4’-dimethoxy-5-hydroxystilbene,
which has methoxy groups located in both the A-ring
and B-ring.Production and purification of methylated resveratrol
analogs in E. coli via artificial biosynthetic pathways
The 3,4’-dimethoxy-5-hydroxystilbene synthesis levels in
the E. coli cells that harbored pET-opTLO13S were not
sufficient for structure elucidation. For a higher produc-
tion of the bis-methylated resveratrol, the recombinant
E. coli cells that harbored pET-opTLO13S were investi-
gated using metabolite pattern analyses according to the
culture times for 85 hours (Figure 6). This recombinant
strain produced a relatively large amount of 3,5-dihy-
droxy-4’-methoxystilbene from the early stages of the
culture. However, at the late stage of the culture, the res-
veratrol was consumed and the production of methylated
resveratrol analogs slightly increased. The production level
of 3,4’-dimethoxy-5-hydroxystilbene (peak 5) increased
following the culturing and a new peak (peak 6) was also
detected that exhibited a more delayed retention time
(Figure 6A). The new peak was identified via LC/MS (m/z
Figure 6 Accumulation of 3,4’-dimethoxy-5-hydroxystilbene and 3,5,4’-trimethoxystilbene in the culture of E. coli harboring
pET-opTLO13S. A. HPLC profile of the time-course cultivation (14, 20, 36, and 64 hours) of E. coli harboring pET-opTLO13S. The cell was
cultured in modified M9 medium at 26°C for (a), 14 hours; (b), 20 hours; (c), 36 hours; (d), 64 hours. p, 4-coumaric acid; peak 1, resveratrol; peak 3,
3,5-dihydroxy-4’-methoxystilbene; peak 5, 3,4’-dimethoxy-5-hydroxystilbene; peak 6, 3,5,4’-trimethoxystilbene. B. Production pattern of one, bis,
and tri-methylated resveratrol in the each culture time. ●, resveratrol; ■, 3,5-dihydroxy-4’-methoxystilbene;▲, 3,4’-dimethoxy-5-hydroxystilbene;
♦. 3,5,4’-trimethoxystilbene. The concentrations were determined through the use of the corresponding chemical standards. All experiments were
performed in triplicates.
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ations of resveratrol (an addition of 42 Da; Additional
file 1: Figure S3). This result represents the methoxy
moiety located at the C-3 and C-5 positions in the A-ring
and the C-4’ position in the B-ring (Figure 1).
In order to obtain NMR-accessible amounts from the
present culture conditions, it was scaled up to 4 liters
of E. coli fermentation that harbored pET-opTLO13S.
Three methylated resveratrol analogs were purified
from the large culture broth. The mass spectra of the
purified methylated resveratrol analogs (3,5-dihydroxy-
4’-methoxystilbene, 3,4’-dimethoxy-5-hydroxystilbene,and 3,5,4’-trimethoxystilbene) are characterized with
mass peaks at m/z 243, 257, and 271 [M + H]+, respect-
ively. The 1H NMR spectra of the purified compounds
were similar to those of the one, bi, and tri-methyl ana-
logs that were isolated, respectively (Additional file 2:
Table S1). The structures of the purified resveratrol
analogs were identified through spectral data interpret-
ation and comparison with the values reported in the lit-
erature [27]. The coexistence of sbOMT1 and sbOMT3
produced a relatively large amount of 3,5-dihydroxy-4’-
methoxystilbene from the early stage of the culture;
however, the pinostilbene was not significantly detected
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superior methylation activity against resveratrol com-
pared with that of sbOMT3. However, at the late stage
of the culture, the production yield of 3,4’-dimethoxy-5-
hydroxystilbene increased; it finally produced tri-methyl
resveratrol (3,5,4’-trimethoxystilbene) (Figure 6B). There-
fore, 3,4’-dimethoxy-5-hydroxystilbene is a major bis-
methylated intermediate in the biosynthesis of 3,5,
4’-trimethoxystilbene in this E. coli system. These re-
sults indicate that sbOMT3 has methylation activity in
the A ring hydroxyl group against resveratrol as well as
3,5-dihydroxy-4’-methoxystilbene. Furthermore, the pres-
ence of 3,5,4’-trimethoxystilbene without the detection of
pterostilbene indicates that the C-5 methylation is ex-
pected to be the final modification step in the coexistence
of the sbOMT1 and sbOMT3 enzymes.
Although the production yield of these compounds is
too low for commercial purposes, the results presented
here were obtained using the wild type E. coil. This is
the first report of an artificial biosynthetic pathway to
obtain methylated resveratrol compounds used a single
vector system joined with resveratrol biosynthetic genes
and two resveratrol O-methyltransferase genes. The
recombinant E. coli produces methylated resveratrol
analogs beginning with simple fermentation rather than
with bioconversion of intermediates. Recently, large-
scale production of plant metabolites via metabolic
engineered microbes has provided a promising alterna-
tive to chemical synthesis and extraction from raw plant
sources [28,29]. Further application with a metabolically
optimized host strain, i.e. a tyrosine and/or malonyl CoA
high producer [23,24], may be very useful for obtaining
industrial scale production yields.
Conclusions
We developed new artificial biosynthetic pathway for
methylated resveratrol compounds using a single vector
system joined with resveratrol biosynthetic genes and
sorghum two resveratrol O-methyltransferase genes. An
E. coli system containing an artificial biosynthetic pathway
produced methylated resveratrol analogs of pinostilbene,
3,5-dihydroxy-4’-methoxystilbene, 3,4’-dimethoxy-5-hydro
xystilbene, and 3,5,4’-trimethoxystilbene from a simple
sugar medium without any precursor feeding. The E. coli
cells that harbored the pET-opTLO1S plasmid (combined
with O-methyltransferase (sbOMT1) and a resveratrol
biosynthetic pathway) produced the one-methyl res-
veratrol analog, 3,5-dihydroxy-4’-methoxystilbene. The
E. coli cells that harbored the pET-opTLO3S plasmid
(combined with O-methyltransferase (sbOMT3) and a
resveratrol biosynthetic pathway) produced the other one-
methyl resveratrol analog, pinostilbene. Furthermore, the
E. coli cells that harbored the pET-opTLO13S (combined
with two sbOMT1 and sbOMT3 O-methyltransferasesand a resveratrol biosynthetic pathway) produced 3,5-di-
hydroxy-4’-methoxystilbene, a bis-methyl resveratrol (3,4’-
dimethoxy-5-hydroxystilbene), and a tri-methyl resveratrol
(3,5,4’-trimethoxystilbene) (Figure 1). The coexistence of
sbOMT1 and sbOMT3 produced 3,5-dihydroxy-4’-meth-
oxystilbene as a major product in the early stage of the
culture; however, the pinostilbene was not significantly
detected (Figure 6). Katsuyama et al. reported the pro-
duction of the pinostilbene and pterostilbene from
E. coli culture using the fungal O-methyltransferase
(OsPMT) gene and the tyrosine feeding medium [15].
Our described strategy exhibits the first harnessing of
microorganisms for the de novo synthesis of methylated
resveratrol analogs using a one-vector system from a
simple sugar without precursor feeding in the culture
medium. Thus, this is also the first report on the pro-
duction of the methylated resveratrol compounds
bis-methyl and tri-methyl resveratrol (3,4’-dimethoxy-
5-hydroxystilbene and 3,5,4’-trimethoxystilbene) in the
E. coli culture. These results provide an opportunity to
create an economic incentive to develop strains cap-
able of converting cheaper feedstock into high value
compounds.
Methods
Bacterial strains, plasmids, and chemicals
E. coli DH5α and E. coli C41 (DE3) [30] were used in
the general DNA manipulation and expression of bio-
synthetic genes, respectively. T-blunt vector (Solgent,
Korea) was used in the polymerase chain reaction (PCR)
cloning. pET-22b(+) and pET-28a(+) were purchased
from Novagen (USA). 4-coumaric acid, resveratrol, pter-
ostilbene, and 3,5,4’-trimethoxystilbene were purchased
from Sigma-Aldrich (USA). Pinostilbene was purchased
from Tokyo Chemical Industry, Co (Japan). IPTG was
purchased from A.G. Scientific, Inc (USA). NMR solvent
was purchased from Cambridge Isotope Laboratories,
Inc. (USA). Hypergrade solvent for LC-MS was pur-
chased from Merck KGaA (Germany).
DNA manipulation
The restriction enzymes (NEB, Takara), Ex taq polymerase
(Takara) pfu taq polymerase (Solgent), and an AccuPower
Ligation kit (Bioneer, Korea) were used according to the
instructions provided by the manufacturers. The codon
optimization and synthesis of tal gene from Saccharothrix
espanaensis (KCTC9392) and the sbOMT1 & sbOMT3
genes [GenBank:ABP01563.1, ABP01564.1] from Sorghum
bicolor were performed using the GeneGPS™ program
(DNA2.0). The sts gene from Arachis hypogaea [GenBank:
AB027606] was codon-optimized and synthesized using
Codon Devices (USA). The ccl gene from Streptomyces
coelicolor A3(2) [GenBank: NP628552] was cloned and
characterized in the laboratory. After the DNA
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the PCR was verified using nucleotide sequencing on an
automated nucleotide sequencer.
Construction of O-methyltransferase expression vectors
and assembly of the artificial biosynthetic pathways
The list of plasmids and strains used in this study can be
found in Table 1. The plasmids were assembled using a
serial stepwise cloning process as previously reported
[18,31]. Briefly, the five genes (TAL, CCL, STS, sbOMT1,
and sbOMT3) were independently cloned into pET-22b(+)
or pET-28a(+) vectors. In order to construct an expression
vector containing the O-methyltransferase genes that
were under the control of independent T7 promoters,
the 1.13-kb and 1.12-kb DNA fragments, which contain the
sbOMT1 and sbOMT3 coding regions, were synthesized
and then cloned into the NdeI and HindIII sites on pET-
22b(+), which resulted in pET22-sbCOM1 and pET22-
sbCOM3, respectively. In order to assemble the vector
containing the methylated resveratrol artificial biosynthetic
pathways, the sbOMT1 and sbOMT3 coding regions
were amplified using pET22-sbCOM1 and pET22-
sbCOM3, respectively, as templates with the primer
NSpe (the sequence is located upstream of the T7 pro-
moter region of the pET vector and contains the designed
SpeI site: ACTAGTAGGTTGAGGCCGTTGAGCACCG
CC) and CSpe (the sequence is located downstream of
the T7 terminator region of the pET vector and contains
the designed SpeI site: ACTAGTTCCTCCTTTCAGC
AAAAAACCCCTC). Each of the amplified fragments
were digested with SpeI and cloned between the SpeI
digested pET-opTLS via ligation, which resulted in pET-
opTLO1S and pET-opTLO3S. In order to construct theTable 1 Plasmids and strains used in this study
Plasmid or strain Relevant characteristics
Plasmids
pET-22b(+) f1 ori, T7 promoter, AmpR
pET-28a(+) f1 ori, T7 promoter, KanR
pET-opTAL pET-28a(+) carrying codon-optimized S
pET-CCL pET-28a(+) carrying CCL from Streptom
pET-KSTS pET-28a(+) carrying codon-optimized A
pET22-sbCOM1 pET-22b(+) carrying codon-optimized S
pET22-sbCOM3 pET-22b(+) carrying codon-optimized S
pET-opTLS pET-28a(+) carrying opTAL, CCL, and KS
pET-opTLO1S pET-28a(+) carrying opTAL, CCL, KSTS, a
pET-opTLO3S pET-28a(+) carrying opTAL, CCL, KSTS, a
pET-opTLO13S pET-28a(+) carrying opTAL, CCL, KSTS, s
Stranis
E. coli DH5a cloning host
E. coli C41(DE3) derivative strain of E. coli BL21(DE3)pET-opTLO13S vectors, the 2.1-kb DNA fragment con-
taining the sbOMT3 coding region was PCR-amplified
with the NPac (the sequence is located upstream of the
T7 promoter region of the pET vector and contains the
designed PacI site: TTAATTAATCGCCGCGACAAT
TTGCGACGG) and CPac (the sequence is located
downstream of the T7 terminator region of the pET
vector and contains the designed PacI site: TTAAT-
TAATGCGCCGCTACAGGGCGCGTCC) primers, re-
spectively, using pET22-sbCOM3 as a template. The
amplified fragment was digested with PacI and cloned
between the PacI digested pET-opTLO1S, which re-
sulted in pET-opTLO13S. The gene sequences and ori-
entations were verified via sequencing after each round
of cloning.
Production of methylated resveratrol analogs
The recombinant E. coli C41 (DE3) strains that harbored
plasmids were precultured overnight at 37°C in a Luria-
Bertani (LB) medium containing 50 μg/mL of appropriate
antibiotics (ampicillin for to maintain the pET-22b(+)-de-
rived plasmids and kanamycin for the pET-28a(+)-derived
plasmids). The overnight culture was inoculated (1.5%)
into a fresh LB medium supplemented with the same
concentration of appropriate antibiotics. The culture
was grown at 37°C to an optical density of 600 nm
(OD600) with 0.6. IPTG being added to the final con-
centration of 1 mM, and the culture was incubated for
6 hours. The cells were harvested via centrifugation,
and then suspended and incubated at 26°C for 36 hours
in a modified M9 medium (M9 medium supplemented
with 15 g/L glucose, 25 g/L CaCO3, 1 mM IPTG and
50 μg/mL appropriate antibiotics). For the feedingSource
Novagen
Novagen
accharothrix espanaensis TAL Kang et al. [31]
yces coelicolor Choi et al. [18]
rachis hypogaea STS Choi et al. [18]
orghum bicolor sbOMT1 This study
orghum bicolor sbOMT3 This study
TS This study
nd sbCOM1 This study
nd sbCOM3 This study
bCOM1, and sbCOM3 This study
Invitrogen
Miroux B & Walker JE [30]
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veratrol (final concentration: 70 μM) and allowed to
grow for an additional 36 hours.
Twenty milliliters of culture was extracted with an equal
volume of ethyl acetate. The ethyl acetate was dried and re-
suspended in 200 μL of methanol. Twenty microliters of
the extract was applied to a J’sphere ODS-H80 column
(4.6 × 150 mm i.d., 5 μm; YMC, Japan) using a high-
performance liquid chromatography (HPLC) system
[CH3CN-H2O (0.05% trifluoroacetic acid(TFA)) 20% to
100% acetonitrile (CH3CN) for 25 min, 100% CH3CN for
5 min, at flow rate of 1 mL/min; Dionex, USA] equipped
with a photodiode array detector. A liquid chromato
graphy-mass spectrometry (LC-MS) was performed using
an LTQ XL linear ion trap (Thermo Scientific, USA)
equipped with an electrospray ionization (ESI) source that
was coupled to a rapid separation LC (RSLC; ultimate
3000, Thermo Scientific) system (ESI-LC–MS) using a
Cosmosil 2.5 Cholester column (Nacalai Tesque, Japan)
(2.0 × 100 mm; 2.5 μm particle size) with a linear gradient
of the binary solvent system under the same HPLC condi-
tions as described above. The ESI (positive ion) parameters
for the methylated resveratrol compounds were the source
voltage (+5KV), entrance capillary voltage (+18 V) entrance
capillary temperature (275°C), and tube lens voltage
(+120 V). The scan range was fixed from m/z 50 to 1000.
The data-dependent mass spectrometry experiments were
controlled using the menu driven software provide with the
Xcalibur system (version 2.2 SP1.48; Thermo Scientific).
The compounds were identified through comparisons with
the standard compounds using the observed retention time,
ultraviolet spectra, and mass chromatogram.
Purification and structural elucidation of the methylated
resveratrol analogs
The recombinant E. coli strains that harbored the pET-
opTLO13S plasmid were cultured via the same method
as described earlier, but the culture volume was in-
creased to 4 liters. The isolation processes were under-
taken as described above. The EtOAc-soluble material
(0.9 g) was further purified by reverse-phase HPLC
(Waters Co., USA) using the YMC J’sphere ODS-H80
(10 × 250 mm, 3 mL/min) with a linear gradient from
20% to 100% CH3CN containing 0.05% TFA in order to
yield 3,5-dihydroxy-4’-methoxystilbene (4.2 mg), 3,4’-
dimethoxy-5-hydroxystilbene (2.1 mg), and 3,5,4’-tri-
methoxystilbene (0.9 mg). The structural elucidation of
the purified compounds was undertaken using 1H NMR
spectroscopy. The NMR experiments were performed on a
Bruker AVANCE 800 spectrometer (800 MHz; Bruker Inc.,
USA) and BarianunityIonva-400 instrument. The structures
of 3,5-dihydroxy-4’-methoxystilbene, 3,4’-dimethoxy-5-hy
droxystilbene and 3,5,4’-trimethoxystilbene were deter-
mined based on the NMR data.Additional files
Additional file 1: Figure S1. SDS-PAGE analysis of the expression of
sbOMT1 and sbOMT3 enzymes in E. coli. Figure S2. Selected mass ion
chromatograms of the pterostilbene (m/z 257.13). Figure S3. Selected
mass ion chromatograms of the 3,5,4’-trimethoxystilbene (m/z 271.14)
produced by E. coli harboring pET-opTLO13S.
Additional file 2: Table S1. Structure elucidation of methylated resveratrol
analogs. 1H NMR spectra of the purified 3,5-dihydroxy-4’-methoxystilbene,
3,4’-dimethoxy-5-hydroxystilbene, and 3,5,4’-trimethoxystilbene and
data from the literature for resveratrol.
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